{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-098861","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.698199+00:00","generated_at":"2026-05-31T08:28:01.945808+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Corbus Pharmaceuticals appoints Winston Kung to Board, replaces exiting director Chip Catlin","bullets":["Avery 'Chip' Catlin resigned from Board and as Audit Chair effective Aug 15, 2024; no disagreement with company.","Winston W. Kung, age 49, appointed to Board effective Aug 16, 2024; will serve as Audit Committee Chair.","Kung is CFO of ArriVent BioPharma; previously COO/CFO at PMV Pharma, VP at Celgene, and roles at Citigroup and Lehman.","Kung receives initial option grant for 5,566 shares and 5,566 RSUs; annual cash retainer $40,000 plus $20,000 for Audit Chair."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-098861","json":"https://secwatch.observer/filing/0000950170-24-098861.json","markdown":"https://secwatch.observer/filing/0000950170-24-098861.md","text":"https://secwatch.observer/filing/0000950170-24-098861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024098861/0000950170-24-098861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024098861/crbp-20240815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:28:01.945808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6695034f9f","claim":"Winston W. Kung was appointed as Director at Corbus Pharmaceuticals Holdings, Inc..","evidence_excerpt":"Effective August 16, 2024, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Winston W. Kung, age 49, to serve as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024098861/0000950170-24-098861-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"edb2bb05ac","claim":"Avery W. Catlin resigned as Director at Corbus Pharmaceuticals Holdings, Inc..","evidence_excerpt":"On August 15, 2024, Avery W. Catlin submitted his resignation from the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), effective as of August 15, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024098861/0000950170-24-098861-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}